cold chain raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-24 and is reviewed periodically as new material appears.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Organic cosolvent may be needed for hydrophobic sequences |
| pH adjustment | Sequence-dependent | Test small volumes before preparing the full solution |
| Filtration | 0.22 µm sterile filter | Can remove particles but may bind or remove aggregates |
| Aliquot size | Single-use volume | Reduces repeated freeze-thaw cycles |
| Post-reconstitution storage | -20 °C to -80 °C | Follow supplier or protocol; avoid frost-free cycles |
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
== References == Chan, E.W.C; S.K. Wong (2009). "Chemical constituents of leaves of Rhizophora x lamarckii, R. apiculata and R. stylosa" (PDF). ISME/GLOMIS Electronic Journal. 7 (1): 1–2. Chan, H.T. (1996). "A note on the discovery of Rhizophora x lamarckii in Peninsular Malaysia" (PDF). Journal of Tropical Forest Science. 9: 128–130. Duke, N.C. (2006). “Australia’s Mangroves: The Authoritative Guide to Australia’s Mangrove Plants”. University of Queensland, Brisbane, 200 p. ISBN 0-646-46196-6. Tomlinson, P.B. (1986). “The Botany of Mangroves”. Cambridge University Press, 413 p. ISBN 0-521-25567-8.
Narrated by John Hedges, produced by Brian Johnson, made by Uden Associates 23 September Trouble on the Line, with Richard Hope and Roger Ford rail journalists, Chris Green, the Head of Network SouthEast; mention of a possible Crossrail and the new Thameslink, which was a redeveloped former freight tunnel; Andrew Higton; Bob Walters the InterCity 225 project engineer; London had the biggest commuter system in world; Borough Market Junction is a bottleneck; Jim Vine head of the new Networker train project; BR carried 700 million people; 134,000 BR employees; at Department of Transport 2300 worked on the roads, and 135 on rail; Dornoch Firth Bridge (A9), shown being built, it saved twenty miles, and could have had a rail bridge too for the Far North Line. Narrated by Anthony Valentine 30 September Fly-by-wire: Technology on Trial 7 October The Light Stuff, about a human-powered aircraft from Santorini to Crete, the MIT Daedalus; the title is from The Right Stuff; the project had taken three years, to fly across the Aegean Sea; the aircraft weighed around 30 kg; to gain the Kremer prize, SUMPAC of the University of Southampton made the first human-powered flight in November 1961, followed by HMPAC Puffin, of de Havilland in Hertfordshire, in May 1962; the Bristol Jupiter flew in 1972; in 1977 Paul MacCready designed his Condor, and his Albatross flew across the English Channel on 12 June 1979, with Bryan Allen; John Langford of MIT developed the Monarch aircraft in 1983, which flew at 21 mph; the Daedalus project began in 1985, to make a 72 mile flight; Steven R.
=== Distinguishing origins of natural gas === Biogenic, thermogenic and abiotic methane is formed at different temperatures, which can be recorded in clumped isotope compositions of methane. Combined with conventional carbon and hydrogen isotope fingerprints and gas wetness (the abundance of low molecular weight hydrocarbon), methane clumped isotope can be used to identify the origins of methane in different types of natural gas accumulations.
Sources: en.wikipedia.org
Microwave relay – a long-distance high bandwidth point-to-point digital data transmission link consisting of a microwave transmitter connected to a dish antenna that transmits a beam of microwaves to another dish antenna and receiver. Since the antennas must be in line-of-sight, distances are limited by the visual horizon to 30–40 miles (48–64 km). Microwave links are used for private business data, wide area computer networks (WANs), and by telephone companies to transmit long-distance phone calls and television signals between cities. Telemetry – automated one-way (simplex) transmission of measurements and operation data from a remote process or device to a receiver for monitoring. Telemetry is used for in-flight monitoring of missiles, drones, satellites, and weather balloon radiosondes, sending scientific data back to Earth from interplanetary spacecraft, communicating with electronic biomedical sensors implanted in the human body, and well logging. Multiple channels of data are often transmitted using frequency-division multiplexing or time-division multiplexing. Telemetry is starting to be used in consumer applications such as: Automated meter reading – electric power meters, water meters, and gas meters that, when triggered by an interrogation signal, transmit their readings by radio to a utility reader vehicle at the curb, to eliminate the need for an employee to go on the customer's property to manually read the meter.
purine Abbreviated in shorthand with the letter R. A double-ringed heterocyclic organic compound which, along with pyrimidine, is one of two molecules from which all nitrogenous bases (including the nucleobases used in DNA and RNA) are derived. Adenine (A) and guanine (G) are classified as purines. The letter R is sometimes used to indicate a generic purine; e.g. in a nucleotide sequence read, R may be used to indicate that either purine nucleobase, A or G, can be substituted at the indicated position.
== Principle == The protein binding principles in EBA are the same as in classical column chromatography and the common ion-exchange, hydrophobic interaction and affinity chromatography ligands can be used. After the adsorption step is complete, the fluidized bed is washed to flush out any remaining particulates. Elution of the adsorbed proteins was commonly performed with the eluent flow in the reverse direction; that is, as a conventional packed bed, in order to recover the adsorbed solutes in a smaller volume of eluent. However, a new generation of EBA columns has been developed, which maintain the bed in the expanded state during this phase, producing high-purity, high yields of e.g. MAbs [monoclonal antibodies] in even smaller volumes of eluent. Process duration at manufacturing scale has also been cut considerably (under 7 hours in some cases). EBA may be considered to combine both the "Removal of Insolubles" and the "Isolation" steps of the 4-step downstream processing heuristic. The major limitations associated with EBA technology is biomass interactions and aggregations onto adsorbent during processing. Where classical column chromatography uses a solid phase made by a packed bed, EBA uses particles in a fluidized state, ideally expanded by a factor of 2. Expanded bed adsorption is, however, different from fluidised bed chromatography in essentially two ways: one, the EBA resin contains particles of varying size and density which results in a gradient of particle size when expanded; and two, when the bed is in its expanded state, local loops are formed.
=== 11 July === Ukraine seized the Cameroonian-flagged cargo vessel Usko Mfu off the coast of Odesa Oblast and arrested its Azerbaijani captain on suspicion of illegally exporting grain produced in Russian-occupied territories of Ukraine via Sevastopol. On the sidelines of the NATO Washington summit, Australia announced its largest military aid package to Ukraine, consisting of A$250 million worth of ammunition, air defence and guided missiles, anti-tank weapons, and boots for soldiers. It was also announced that the ADF would join the newly established NATO command for Ukraine.
Sources: en.wikipedia.org
Full analgesic efficacy of buprenorphine requires both exon 11- and exon 1-associated μ-opioid receptor splice variants. The active metabolites of buprenorphine are not thought to be clinically important in its CNS effects. In positron emission tomography (PET) imaging studies, buprenorphine was found to decrease whole-brain MOR availability due to receptor occupancy by 41% (i.e., 59% availability) at 2 mg, 80% (i.e., 20% availability) at 16 mg, and 84% (i.e., 16% availability) at 32 mg.
Nalfurafine (INN, USAN; brand name Remitch; former developmental code names TRK-820, AC-820, MT-9938) is an antipruritic (anti-itch drug) that is marketed in Japan for the treatment of uremic pruritus in individuals with chronic kidney disease undergoing hemodialysis. It activates the κ-opioid receptor (KOR) and is potent, selective, and centrally active. It was the first selective KOR agonist approved for clinical use. It has also been dubiously referred to as the "first non-narcotic opioid drug" in history.
Chemical information, Clinical information and Biochemical information. The chemical data includes >40,000 metabolite structures with detailed descriptions, extensive chemical classifications, synthesis information and observed/calculated chemical properties. It also contains nearly 10,000 experimentally measured NMR, GC-MS and LC/MS spectra from more than 1,100 different metabolites. The clinical information includes data on >10,000 metabolite-biofluid concentrations, metabolite concentration information on more than 600 different human diseases and pathway data for more than 200 different inborn errors of metabolism. The biochemical information includes nearly 6,000 protein (and DNA) sequences and more than 5,000 biochemical reactions that are linked to these metabolite entries. The HMDB supports a wide variety of online queries including text searches, chemical structure searches, sequence similarity searches and spectral similarity searches. This makes it particularly useful for metabolomic researchers who are attempting to identify or understand metabolites in clinical metabolomic studies. The first version of the HMDB was released in Jan. 1 2007 and was compiled by scientists at the University of Alberta and the University of Calgary. At that time, they reported data on 2,500 metabolites, 1,200 drugs and 3,500 food components. Since then these scientists have greatly expanded the collection. The version 3.5 of the HMDB contains >16,000 endogenous metabolites, >1,500 drugs and >22,000 food constituents or food metabolites.
==== Yogācāra ==== The yogācāra school interpreted the doctrine of dependent origination through its central schema of the "three natures" (which are really three ways of looking at one dependently originated reality). In this schema, the constructed or fabricated nature is an illusory appearance (of a dualistic self), while the "dependent nature" refers specifically to the process of dependent origination or as Jonathan Gold puts it "the causal story that brings about this seeming self." Furthermore, as Gold notes, in Yogacara, "this causal story is entirely mental," and so our body, sense bases and so on are illusory appearances. Indeed, D.W. Mitchell writes that yogācāra sees consciousness as "the causal force" behind dependent arising. Dependent origination is therefore "the causal series according to which the mental seeds planted by previous deeds ripen into the appearance of the sense bases". This "stream of dependent mental processes" as Harvey describes it, is what generates the subject-object split (and thus the idea of a '"self" and "other" things which are not the self). The third nature then, is the fact that dependent origination is empty of a self, the fact that even though self (as well as an "other", that which is apart from the self) appears, it does not exist.
=== Licensing status === The Orion Corporation originally developed levosimendan and applied for a new drug application in 1998 in the U.S. However the Food and Drug Administration (FDA) requested further trials be conducted and Orion withdrew the application in November 1999. Initially, Orion obtained the approval to market the drug in Sweden in 2000. Since then 60 countries worldwide have approved the drug for acute cardiac care, but it remains unapproved in North America, where it is currently in Phase III development by Tenax Therapeutics for reduction in morbidity in patients with Pulmonary Hypertension derived from Heart Failure with preserved Ejection Faction (PH-HFpEF).
Sources: en.wikipedia.org
It should first equilibrate to room temperature in a sealed container to prevent condensation on the cold contents. Opening too soon can introduce moisture and reduce stability, and the waiting period depends on vial size and packaging.
Hydrophobic peptides may require buffers, organic cosolvents, or a stepwise solvent approach. Small amounts of acetonitrile, methanol, or dimethyl sulfoxide are sometimes used, followed by dilution into aqueous buffer. The exact solvent system should be tested for the specific sequence.
Single-use aliquots limit freeze-thaw cycling, which can cause aggregation, precipitation, or loss of activity. They also reduce repeated opening of the same container and lower contamination risk. Labeling each aliquot supports traceability and consistent use.
Work quickly in a dry environment and keep the container closed when not in use. Equilibrate sealed vials to room temperature before opening to reduce condensation. Record mass changes, as absorbed water can affect concentration calculations.